Mersana Therapeutics, Inc. announced today that it has achieved its second preclinical milestone in its collaboration with Endo Pharmaceuticals. In 2012, Mersana and Endo entered into a multi-target, oncology focused partnership to develop next-generationFleximer® antibody-drug conjugates (ADCs).
“We are pleased that this novel Fleximer-ADC has passed yet another important milestone as it advances toward clinical development,” said Timothy Lowinger, Ph.D., Chief Scientific Officer of Mersana. “The rapid progress made on this molecule since the last milestone provides further validation that our proprietary conjugation technology and Fleximer polymer make an optimal platform for the development of next-generation ADCs.”
“We are very pleased to see that this novel ADC has successfully completed pilot toxicology assessments,” said Sandeep Gupta, Ph.D., Senior Vice President of Discovery and Early Development at Endo. “Taken together with the excellent efficacy observed in numerous pre-clinical cancer models, we are excited about the potential this molecule has for the treatment of a variety of cancer types.”
The collaboration between Mersana and Endo leverages Mersana’s proprietary conjugation technology, comprised of the Fleximer® polymer and a broad array of customizable linker chemistries for attaching diverse, potent payloads to antibodies. Under the terms of the agreement, Mersana is responsible for conducting research and creating Fleximer-ADC development candidates with antibodies provided by Endo. The rights to these ADCs have been licensed to Endo in exchange for research funding, milestone payments and royalties on worldwide net sales of any resulting ADC products.
Published in: Mersana Therapeutics, Inc. Website